Genetic Association of the KLK4 Locus with Risk of Prostate Cancer

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Lose, Felicity ^a,b   Srinivasan, Srilakshmi ^b   O'Mara, Tracy ^a,b   Marquart, Louise ^a   Chambers, Suzanne ^c,d,e   Gardiner, Robert A ^e   Aitken, Joanne F ^c,d   Yeadon, Trina ^b   Saunders, Pamela ^b   Eckert, Allison ^b   Clements, Judith ^b   Heathcote, Peter ^f   Wood, Glenn ^f   Malone, Greg ^f   Samaratunga, Hema ^g   Collins, Angus ^h   Turner, Megan ^h   Kerr, Kris ^h   Spurdle, Amanda B ^a,b   Batra, Jyotsna ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

^d CANCER COUNCIL QUEENSLAND   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f Brisbane Urology Clinic Central Queensland Urology Clinic   (Australia)

^g Aquesta Uro Pathology   (Australia)

^h SULLIVAN NICOLAIDES PATHOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; KALLIKREIN RELATED PEPTIDASE; PEPTIDASE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84866060232     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044520     Document Type: Article

References (51)

1. Lawrence MG, Lai J, Clements JA, (2010) Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev 31: 407-446.
2. Mavridis K, Scorilas A, (2010) Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncol 6: 269-285.
3. Nelson PS, Gan L, Ferguson C, Moss P, Gelinas R, et al. (1999) Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Natl Acad Sci U S A 96: 3114-3119.
4. Yousef GM, Obiezu CV, Luo LY, Black MH, Diamandis EP, (1999) Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. Cancer Res 59: 4252-4256.
5. Obiezu CV, Shan SJ, Soosaipillai A, Luo LY, Grass L, et al. (2005) Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. Clin Chem 51: 1432-1442.
6. Avgeris M, Stravodimos K, Scorilas A, (2011) Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance. Prostate 71: 1780-1789.
7. Day CH, Fanger GR, Retter MW, Hylander BL, Penetrante RB, et al. (2002) Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera. Oncogene 21: 7114-7120.
8. Obiezu CV, Soosaipillai A, Jung K, Stephan C, Scorilas A, et al. (2002) Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clin Chem 48: 1232-1240.
9. Xi Z, Klokk TI, Korkmaz K, Kurys P, Elbi C, et al. (2004) Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res 64: 2365-2370.
10. Klokk TI, Kilander A, Xi Z, Waehre H, Risberg B, et al. (2007) Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res 67: 5221-5230.
11. Dong Y, Bui LT, Odorico DM, Tan OL, Myers SA, et al. (2005) Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms. Endocr Relat Cancer 12: 875-889.
12. Kurlender L, Borgono C, Michael IP, Obiezu C, Elliott MB, et al. (2005) A survey of alternative transcripts of human tissue kallikrein genes. Biochim Biophys Acta 1755: 1-14.
13. Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, Herington AC, et al. (2005) Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer 12: 631-643.
14. Gao J, Collard RL, Bui L, Herington AC, Nicol DL, et al. (2007) Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer. Prostate 67: 348-360.
15. Seiz L, Kotzsch M, Grebenchtchikov NI, Geurts-Moespot AJ, Fuessel S, et al. (2010) Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer. Biol Chem 391: 391-401.
16. Gronberg H, (2003) Prostate cancer epidemiology. Lancet 361: 859-864.
17. Hindorff LA, Junkins HA, Hall PN, Mehta JP, Manolio TA (2010) A Catalog of Published Genome-Wide Association Studies.
18. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, et al. (2008) Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40: 316-321.
19. Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, et al. (2008) Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev 17: 2052-2061.
20. Eeles RA, Giles GG, Neal DE, Muir K, Easton DF, (2008) Reply to "Variation in KLK genes, prostate-specific antigen and risk of prostate cancer". Nat Genet 40: 1035-1036.
21. Kote-Jarai Z, Amin Al Olama A, Leongamornlert D, Tymrakiewicz M, Saunders E, et al. (2011) Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet 129: 687-694.
22. The International HapMap Consortium, (2003) The International HapMap Project. Nature 426: 789-796.
23. 1000 Genome Project Consortium (2010) A map of human genome variation from population-scale sequencing. Nature 467: 1061-1073.
24. Lose F, Batra J, O'Mara T, Fahey P, Marquart L, et al. (2011) Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. Urol Oncol.
25. Baade PD, Aitken JF, Ferguson M, Gardiner RA, Chambers SK, (2010) Diagnostic and treatment pathways for men with prostate cancer in Queensland: investigating spatial and demographic inequalities. BMC Cancer 10: 452.
26. Lai J, Kedda MA, Hinze K, Smith RL, Yaxley J, et al. (2007) PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis 28: 1032-1039.
27. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, et al. (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29: 308-311.
28. Riva A, Kohane IS, (2004) A SNP-centric database for the investigation of the human genome. BMC Bioinformatics 5: 33.
29. Goard CA, Bromberg IL, Elliott MB, Diamandis EP, (2007) A consolidated catalogue and graphical annotation of dbSNP polymorphisms in the human tissue kallikrein (KLK) locus. Mol Oncol 1: 303-312.
30. Amigo J, Salas A, Phillips C, Carracedo A, (2008) SPSmart: adapting population based SNP genotype databases for fast and comprehensive web access. BMC Bioinformatics 9: 428.
31. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, et al. (2007) Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 39: 645-649.
32. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, et al. (2008) SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 24: 2938-2939.
33. Barrett JC, Fry B, Maller J, Daly MJ, (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
34. Lose F, Nagle CM, O'Mara T, Batra J, Bolton KL, et al. (2010) Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecol Oncol 119: 479-483.
35. Lai J, Myers SA, Lawrence MG, Odorico DM, Clements JA, (2009) Direct progesterone receptor and indirect androgen receptor interactions with the kallikrein-related peptidase 4 gene promoter in breast and prostate cancer. Mol Cancer Res 7: 129-141.
36. Grabe N (2000) AliBaba2.1.
37. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, et al. (1998) Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26: 362-367.
38. Akiyama Y (2002) TFSEARCH: Searching Transcription Factor Binding Sites.
39. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, et al. (2005) MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21: 2933-2942.
40. Gonzalez MI, Robins DM, (2001) Oct-1 preferentially interacts with androgen receptor in a DNA-dependent manner that facilitates recruitment of SRC-1. J Biol Chem 276: 6420-6428.
41. Obinata D, Takayama K, Urano T, Murata T, Kumagai J, et al. (2012) Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer. Int J Cancer 130: 1021-1028.
42. Wilkinson R, Woods K, D'Rozario R, Prue R, Vari F, et al. (2012) Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer Immunol Immunother 61: 169-179.
43. Bendtsen JD, Nielsen H, von Heijne G, Brunak S, (2004) Improved prediction of signal peptides: SignalP 3.0. J Mol Biol 340: 783-795.
44. Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, et al. (2001) A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61: 6958-6963.
45. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, et al. (2011) A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185: 1650-1655.
46. Kaushal A, Myers SA, Dong Y, Lai J, Tan OL, et al. (2008) A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus. Prostate 68: 381-399.
47. Zuker M, (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31: 3406-3415.
48. Klein RJ, Hallden C, Cronin AM, Ploner A, Wiklund F, et al. (2010) Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prev Res (Phila) 3: 611-619.
49. Lee JY, Park AK, Lee KM, Park SK, Han S, et al. (2009) Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women. Carcinogenesis 30: 1528-1531.
50. Ciampa J, Yeager M, Amundadottir L, Jacobs K, Kraft P, et al. (2011) Large-scale exploration of gene-gene interactions in prostate cancer using a multistage genome-wide association study. Cancer Res 71: 3287-3295.
51. Mize GJ, Wang W, Takayama TK, (2008) Prostate-specific kallikreins-2 and-4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and-2. Mol Cancer Res 6: 1043-1051.